Skip to main content

Advertisement

Table 3 Chemoradiotherapy-related acute adverse events in the matched cohort

From: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Adverse event Docetaxel group [cases (%)] Cisplatin group [cases (%)] P value
Grade 1–2 Grade 3 Grade 1–2 Grade 3
Leucopenia 90 (40.2) 5 (2.2) 164 (73.2) 26 (11.6) < 0.001
Anemia 55 (24.6) 0 105 (46.8) 2 (0.9) < 0.001
Thrombocytopenia 3 (1.3) 0 41 (18.3) 4 (1.8) < 0.001
ALT elevation 42 (18.8) 1 (0.4) 68 (30.4) 2 (0.9) 0.027
CCR elevation 4 (1.8) 0 33 (14.7) 1 (0.4) < 0.001
Vomitinga 42 (18.8) 0 185 (82.5) 13 (5.8) < 0.001
Mucositisa 45 (20.1) 167 (74.5) 102 (45.5) 85 (37.9) < 0.001
Weight lossa 171 (76.3) 0 166 (74.1) 2 (0.1) 0.010
Radiodermatitisa 191 (85.3) 15 (6.7) 185 (82.6) 4 (1.8) 0.001
Tinnitusa 23 (10.3) 0 24 (10.7) 0 0.835
Xerostomiaa 171 (76.3) 2 (0.1) 170 (75.9) 2 (0.1) 0.052
  1. Only one patient in the cisplatin group had grade 4 radiodermatitis
  2. ALT Alanine transaminase, AST aspartate aminotransferase, CCR creatinine clearance
  3. aMissing value: In the docetaxel group, medical records of 10 patients were missing for radiodermatitis, mucositis, and xerostomia, 8 for vomiting, 6 for weight loss, and 12 for tinnitus; In the cisplatin group, medical records of 35 patients were missing for radiodermatitis, 37 for mucositis, 38 for xerostomia, 9 for vomiting, 17 for weight loss, and 38 for tinnitus